Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Rare save search
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Published: 2023-10-14 (Crawled : 00:20) - globenewswire.com
MREO | $2.79 5.68% 5.38% 1.1M
|
Health Technology
| Email alert
Add to watchlist
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
| Email alert
Add to watchlist
ux143 biopharma study phase 2
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
Published: 2022-04-20 (Crawled : 12:20) - globenewswire.com
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
|
| O: -0.15%
H: 1.14%
C: 0.06%
MREO | $2.79 5.68% 5.38% 1.1M
|
Health Technology
|
| O: 3.09%
H: 0.0%
C: -9.78%
ux143 treatment phase 2
Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
|
| O: 2.82%
H: 0.06%
C: -6.28%
gene therapy multi-year phase 1 positive therapy phase 2 phase 3
Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Published: 2021-10-01 (Crawled : 21:00) - globenewswire.com
MREO | $2.79 5.68% 5.38% 1.1M
|
Health Technology
| Email alert
Add to watchlist
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
| Email alert
Add to watchlist
phase 2 biopharma bone phase 2b research
Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting
Published: 2021-05-14 (Crawled : 13:00) - globenewswire.com
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
|
| O: 1.39%
H: 3.38%
C: 2.49%
ongoing phase 1 gene therapy positive therapy multi-year phase 3 phase 2 gene therapies
Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramPhase 3 Study on Track to Initiate in Second Half 2021
Published: 2021-04-22 (Crawled : 14:00) - biospace.com/
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
|
| O: 0.39%
H: 2.14%
C: -0.64%
fda phase 2 gene therapy therapy phase 3 gene therapies designation
Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies
Published: 2021-01-08 (Crawled : 14:03) - globenewswire.com
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
|
| O: 0.03%
H: 5.3%
C: 3.53%
gene therapy positive therapy phase 3 phase 1 phase 2 gene therapies
GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome
Published: 2020-12-05 (Crawled : 18:01) - globenewswire.com
RARE F | $43.705 3.15% 3.05% 590K
|
Health Technology
| Email alert
Add to watchlist
phase 3 phase 1 phase 2 syndros
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.